ADHD Trial, Recruiting NCT07105475 Sponsor: Ben-Gurion University of the Negev Condition: ADHD
Back to Adhd

ADHD Trial, Recruiting

NCT07105475
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between the ages of 21 and 65 (men and women).
  • People who have been diagnosed with ADHD according to the DSM-5 diagnostic guidelines.
  • People currently taking ADHD medication who are willing to switch to a short-acting form of Ritalin (10mg, with the possibility of increasing to 20mg per dose) for the duration of the study — taken at least 8 hours before treatment sessions or at least 1 hour after, including on follow-up days. This is to ensure that any changes observed are due to the study treatment, not the medication.
  • People who are willing to provide both written and verbal consent to take part in the study.

Who may not be able to join:

  • People who have another active psychiatric diagnosis listed under Axis I of the DSM-5.
  • People currently taking antipsychotic medications, antidepressants, or mood stabilisers.
  • People who have previously had a bad reaction or intolerance to TMS (a type of brain stimulation).
  • People who have been diagnosed with a severe personality disorder according to DSM-5 criteria.
  • People who are currently experiencing suicidal thoughts or urges.
  • People with high blood pressure that is not well controlled.
  • People with a personal history of epilepsy, seizures, or febrile (fever-related) seizures.
  • People who have a close biological relative (parent, sibling, or child) with a history of epilepsy or seizures.
  • People who have had a head injury or major stroke that caused lasting impairment.
  • People who have metal in their head (not including dental work inside the mouth).
  • People with a history of surgery involving metal implants, metal particles in the eye, a pacemaker, an implanted hearing device, a neurostimulator, or any medical pump implanted in the body.
  • People with a history of drug or alcohol addiction.
  • People who are unable to communicate adequately with the study examiner.
  • People who are currently participating in another medical study, or who have done so within the past 3 months.
  • People who are unable to sign a consent form.
  • People who are pregnant, or who are unwilling to commit to avoiding pregnancy or to using contraception during the study period.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Abraham Zangen, Ben-Gurion University of the Negev

Phone: +972 8-647-2646

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ben-Gurion University of the Negev
Registry
ClinicalTrials.gov
Start date
19 July 2023
Est. completion
1 September 2027

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Change in ADHD Symptoms Assessed by the Conners' Adult ADHD Rating Scale (CAARS); Change in Cognitive Control Assessed by Stroop Task Performance; Change in Working Memory Assessed by N-back Task Performance; Change in EEG Power Spectral Density Across Frequency Bands; Change in Raw EEG Voltage

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov